Financial Performance - The company's operating revenue for Q1 2022 was ¥49,375,230.28, representing a decrease of 2.89% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥18,245,252.74, down 6.20% year-on-year[5]. - The basic and diluted earnings per share were both ¥0.22, reflecting a decline of 8.33%[6]. - Total operating revenue for Q1 2022 was ¥49,375,230.28, a decrease of 2.9% from ¥50,843,046.14 in Q1 2021[17]. - Net profit for Q1 2022 was ¥18,245,252.74, a decline of 6.2% compared to ¥19,451,138.70 in Q1 2021[18]. - Total comprehensive income for Q1 2022 was ¥18,245,252.74, reflecting a decrease from ¥19,451,138.70 in Q1 2021[18]. Cash Flow and Expenses - The net cash flow from operating activities was ¥3,134,398.13, down 51.43% compared to the previous year[5]. - Cash flow from operating activities for Q1 2022 was ¥3,134,398.13, a decrease of 51.4% from ¥6,453,318.56 in Q1 2021[21]. - Cash and cash equivalents are reported at ¥1,301,664,616.24, down from ¥1,322,459,728.04[12]. - Cash and cash equivalents at the end of Q1 2022 were ¥1,293,439,304.66, down from ¥1,268,883,343.77 at the end of Q1 2021[22]. - Research and development expenses totaled ¥3,797,490.64, accounting for 7.69% of operating revenue, a decrease of 0.42 percentage points[6]. - Research and development expenses for Q1 2022 were ¥3,797,490.64, a decrease of 7.9% from ¥4,124,300.79 in Q1 2021[17]. - The company reported a decrease in tax expenses for Q1 2022, totaling ¥3,282,864.18, compared to ¥3,212,740.98 in Q1 2021[18]. - Financial expenses for Q1 2022 showed an improvement, with a net income of -¥6,635,861.10 compared to -¥7,581,711.43 in Q1 2021[17]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,494,380,159.07, an increase of 0.72% from the end of the previous year[6]. - Total current assets as of March 31, 2022, amount to ¥1,379,035,264.41, a slight decrease from ¥1,388,458,729.56 at the end of 2021[13]. - The company's total assets as of March 31, 2022, are ¥1,494,380,159.07, compared to ¥1,483,743,725.61 at the end of 2021[13]. - Total liabilities decreased to ¥55,273,251.88 from ¥62,882,071.16, a reduction of approximately 12.5%[14]. - The retained earnings increased to ¥284,863,824.19 from ¥266,618,571.45, showing a growth of about 6.8%[14]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,308[10]. - The largest shareholder, Wu Shiming, holds 28,298,431 shares, representing 34.66% of total shares[10]. Operational Insights - The company noted that the decrease in operating revenue was partly due to the increased impact of COVID-19 in certain regions[8]. - The company experienced a significant increase in prepayments by 225.08%, attributed to higher advance payments for materials[8]. - The cash flow from investment activities increased significantly by ¥6,804,330 due to increased expenditures on the Daxing base project[8]. - Inventory as of March 31, 2022, is ¥40,727,656.05, up from ¥38,420,659.14, indicating an increase of about 6.0%[13]. - Accounts receivable increased to ¥28,331,387.35 from ¥24,472,934.35, reflecting a growth of approximately 15.3%[12]. - The company has not reported any new product developments or market expansion strategies in the current quarter[12].

Financial Performance - The proposed profit distribution plan for 2021 includes a cash dividend of RMB 2.5 per 10 shares, totaling RMB 20,412,000, which accounts for 20.96% of the net profit attributable to shareholders[5]. - The company has not yet achieved profitability since its listing[4]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[14]. - In 2021, the company's operating revenue reached ¥239,915,362.66, representing a year-on-year increase of 7.88% compared to ¥222,398,393.41 in 2020[22]. - The net profit attributable to shareholders increased by 40.73% to ¥97,368,830.48 in 2021, up from ¥69,188,424.17 in 2020[24]. - The net cash flow from operating activities increased by 48.65% to ¥107,423,198.26 in 2021, up from ¥72,266,743.41 in 2020[24]. - The company achieved operating revenue of ¥239,915,362.66, a year-on-year increase of 7.88%[33]. - The company reported a significant increase in cash inflows from sales and interest income, contributing to the rise in operating cash flow[24]. Risk Management - The company has detailed various operational risks in the report, urging investors to be cautious[4]. - The company has a comprehensive risk factor section in the report for investor reference[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The company faces risks related to technological iteration and the long R&D cycle of in vitro diagnostic products, which may impact its competitive position if not addressed[81]. - The company relies on foreign suppliers for key raw materials, which poses risks related to import dependency and supply chain stability[83]. - The company faces risks related to reliance on imported raw materials, which could impact production if supply chain disruptions occur[84]. - The company is exposed to potential price reductions due to stricter government regulations on medical device pricing[87]. Research and Development - Research and development expenses increased by 30%, totaling 150 million RMB, focusing on advanced technologies in the healthcare sector[14]. - The R&D expenditure as a percentage of operating revenue increased to 6.34% in 2021, up from 6.01% in 2020[23]. - The company has developed 15 core technologies and holds 29 patents, including 8 invention patents, demonstrating strong independent research and development capabilities[47]. - The company has established a core technology cluster covering instruments, reagents, and consumables, with five major technology categories including blood rheology measurement and coagulation diagnostic testing[52]. - The company is focusing on the integration of automation and motion control technologies in the development of platelet aggregation products for clinical diagnosis[53]. - The company is actively expanding its product offerings and improving its technology through ongoing research and development initiatives[66]. - The company has established a strong brand presence in the thrombus and hemostasis in vitro diagnostic market, with over 9,000 domestic terminal medical institution users[193]. Corporate Governance - The board of directors has confirmed the authenticity and completeness of the annual report[5]. - The company has not disclosed any special arrangements for corporate governance[7]. - The governance structure of the company aligns with the regulatory requirements set forth by the China Securities Regulatory Commission[128]. - The company has established a robust investor relations management system to enhance communication and transparency with investors[130]. - The board of directors is composed of members who strictly adhere to the company's articles of association and relevant laws, ensuring compliance and effective governance[129]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors and regulatory bodies[130]. - The company has maintained independence from its controlling shareholder in business, personnel, assets, and financial matters, ensuring autonomous operational capability[131]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[14]. - International sales revenue grew by 68.09%, enhancing the company's brand influence in regions such as the Middle East, Asia, and South America[35]. - The company has established a nationwide marketing service network, covering 29 provinces and key cities, serving tertiary and secondary hospitals[79]. - The company aims to expand its production capacity through the construction of a new production base and the addition of equipment and personnel[124]. - The marketing strategy includes strengthening the domestic marketing network and targeting large public hospitals and third-party testing institutions[125]. Employee and Operational Management - The company has a structured training program for new employees to ensure quick integration into the team[196]. - The company has implemented a comprehensive training program, including onboarding, skills training, and knowledge sharing, to enhance employee capabilities[169]. - The company has achieved a 100% labor contract signing rate, ensuring compliance with labor laws and protecting employee rights[195]. - The company provides various employee benefits, including paid annual leave, communication subsidies, and travel insurance for employees frequently on business trips[196]. - The company has conducted various training programs in 2021, focusing on new employee onboarding, job skills, and business knowledge[195]. Environmental Responsibility - The company is committed to sustainable development, focusing on environmental protection and social responsibility while promoting green practices in its operations[179]. - The company has implemented appropriate measures for wastewater, noise, and solid waste treatment, ensuring compliance with environmental protection laws and regulations[186]. - The company has taken measures to reduce carbon emissions by improving production processes and conserving energy[190]. - The company has established environmental management standards and procedures, including waste disposal management and wastewater treatment[189]. Shareholder Information - The total number of shares held by directors, supervisors, and senior management at the end of the reporting period was 37,303,483, a decrease of 489,218 shares during the year[135]. - The company has a well-defined cash dividend distribution mechanism, with clear decision-making processes and protection for minority shareholders' rights[174]. - The company has established a long-term effective cash dividend policy to ensure continuity and stability in dividend distribution, protecting the rights of shareholders, especially minority investors[172]. - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares, totaling RMB 20,412,000, which represents 20.96% of the net profit attributable to shareholders for 2021[173].

Financial Performance - The company's revenue for Q3 2021 was ¥53,462,283.47, representing a year-on-year increase of 2.93%[5] - Net profit attributable to shareholders was ¥25,315,625.17, up 67.52% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses was ¥21,889,090.45, an increase of 44.98% year-on-year[5] - Basic earnings per share were ¥0.31, reflecting a 93.79% increase compared to the previous year[6] - Total operating revenue for the first three quarters of 2021 reached ¥164,152,824.88, an increase of 8.4% compared to ¥151,135,602.87 in the same period of 2020[21] - Net profit for the first three quarters of 2021 was ¥67,039,891.03, up 66.9% from ¥40,158,932.04 in the previous year[22] - Earnings per share for the period was ¥0.82, compared to ¥0.57 in the same period last year, reflecting a 43.9% increase[22] - The company reported a total profit of ¥76,696,181.38 for the first three quarters, an increase of 62.1% from ¥47,335,283.68 in the same period of 2020[22] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date was ¥58,050,438.23, showing a significant increase of 97.07%[5] - Operating cash inflow for Q3 2021 was CNY 214,679,023.96, an increase from CNY 191,503,072.86 in Q3 2020, representing a growth of approximately 12.1%[25] - Net cash flow from operating activities was CNY 58,050,438.23, significantly up from CNY 29,456,685.13 in the same period last year, indicating a year-over-year increase of about 96.5%[25] - Cash outflow from investment activities totaled CNY 1,271,040.70, a decrease from CNY 31,059,154.12 in Q3 2020, reflecting a reduction of approximately 95.9%[26] - Net cash flow from financing activities was negative CNY 35,431,435.32, compared to a positive CNY 912,623,588.23 in Q3 2020, showing a significant decline[26] - The ending balance of cash and cash equivalents was CNY 1,283,998,568.75, up from CNY 1,231,494,688.84 at the end of Q3 2020, marking an increase of about 4.3%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,441,027,266.93, a growth of 2.82% from the end of the previous year[6] - Total assets reached CNY 1.44 billion, an increase from CNY 1.40 billion at the end of 2020[18] - Total liabilities increased to ¥50,494,551.93 from ¥45,312,936.30, marking an increase of 11.9%[19] - Total equity attributable to shareholders rose to ¥1,390,532,715.00 from ¥1,356,152,023.97, an increase of 2.5%[19] - Current liabilities totaled 43,743,257.64, with a significant portion attributed to employee compensation and taxes payable[30] - Non-current liabilities rose to 5,294,926.81, primarily due to lease liabilities of 3,725,248.15[30] Research and Development - Research and development expenses totaled ¥3,546,751.06, accounting for 6.63% of revenue, which is an increase of 0.08 percentage points[6] - Research and development expenses for the first three quarters were ¥11,887,089.91, up from ¥10,203,118.14, indicating a growth of 16.5%[21] - The company obtained 1 new invention patent during the reporting period, and 5 new in vitro diagnostic reagent products completed the registration assessment phase[15] Government Support and Subsidies - The company received government subsidies amounting to ¥4,035,210.62 during the reporting period, contributing to other income[9] Market and Future Plans - The company plans to continue expanding its market presence and investing in new technologies, although detailed figures and timelines were not provided in the report[26] - The company is advancing the construction of its integrated production and R&D project for thrombosis and hemostasis products, having obtained the necessary planning permits[15] Financial Reporting Changes - The company has implemented new leasing standards starting in 2021, which may affect future financial reporting and cash flow management[26] - The earnings report was officially announced on October 27, 2021, by the board of directors[32]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1] - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2021, representing a 15% year-over-year growth[15] - The company's operating revenue for the first half of 2021 increased by 11.59% year-on-year, reaching approximately ¥110.69 million, primarily due to the effective control of the domestic COVID-19 pandemic[22] - The net profit attributable to shareholders for the same period grew by 66.59% year-on-year, amounting to approximately ¥41.72 million, driven by an increase in operating revenue and a reduction in financial expenses[23] - The net cash flow from operating activities surged by 93.87% year-on-year, totaling approximately ¥36.83 million, attributed to higher cash receipts from sales and other operating activities[23] - The company achieved a revenue of 110.69 million yuan in the first half of 2021, representing a year-on-year increase of 11.59%[62] - The net profit attributable to shareholders reached 41.72 million yuan, up 66.59% year-on-year, while the net profit after deducting non-recurring gains and losses was 40.27 million yuan, an increase of 43.06%[63] User Growth - User data indicates a growth in active users by 15% compared to the previous year, reaching a total of 1.5 million active users[1] - User data indicates a growth in active users, with a 20% increase compared to the previous year, reaching 500,000 active users[15] Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region by the end of 2021[1] - The company is expanding its market presence, targeting new regions in Asia, which is anticipated to contribute an additional 5% to overall revenue growth[15] - The company has established a nationwide marketing service network covering 29 provinces and key cities, excluding Tibet, Qinghai, and Hong Kong and Macau[60] Product Development - New product development includes the launch of a next-generation diagnostic kit, projected to increase market share by 10%[1] - New product development includes the launch of a next-generation diagnostic tool, expected to enhance market competitiveness and drive sales growth[15] - The company has completed clinical trials for several new products, including D-Dimer test kits and AT reagent kits, which are expected to enhance its product offerings in the market[52] - The company has developed a core technology cluster covering instruments, reagents, and consumables, with 15 core technologies and 27 patents, including 6 invention patents[31] Research and Development - Research and development expenses have increased by 15%, reflecting the company's commitment to innovation and new technology[1] - The company plans to invest 200 million RMB in R&D for the upcoming year to support innovation and product development[15] - The company's R&D expenditure as a percentage of operating revenue rose to 7.53%, an increase of 0.68 percentage points compared to the previous year[22] - The company has achieved a 22.67% increase in research and development expenses, totaling ¥8,340,338.85, compared to ¥6,799,162.81 in the previous period[47] - The company has 15 ongoing R&D projects, focusing on the development of high-performance fully automated coagulation testing instruments and specialized coagulation detection reagents[63] Strategic Acquisitions - The company has completed a strategic acquisition of a local competitor, which is expected to enhance its product offerings and increase revenue by an estimated RMB 50 million annually[1] - A strategic acquisition of a smaller biotech firm was completed, which is expected to enhance the company's R&D capabilities and product offerings[15] Compliance and Risk Management - The company emphasizes the importance of compliance with regulatory requirements to mitigate risks associated with financial reporting[1] - The company has identified potential risks in supply chain disruptions, which may impact future performance if not addressed[1] - The company faces technology iteration risks in the field of thrombus and hemostasis in vitro diagnostic products due to potential revolutionary changes in technology by competitors[65] - The company relies on foreign suppliers for key raw materials, such as D-Dimer B3 Bulk and FDP Bulk, which poses risks related to import dependency and potential supply chain disruptions[68] Environmental Compliance - The company has maintained compliance with environmental regulations, with no penalties reported during the reporting period[87] - The company operates its in vitro diagnostic reagent production facility in Changping District, Beijing, with environmental impacts including wastewater, noise, and solid waste management[88] - Wastewater from production is treated and reused for toilet flushing, while domestic wastewater is processed at the Changping sewage treatment center[88] Shareholder Commitments - The controlling shareholder, Wu Shiming, has committed to a 36-month lock-up period for shares post-IPO, during which no shares will be transferred or managed by others[97] - The commitments will remain effective as long as the controlling shareholders hold significant influence over the company[118] - The company commits to the accuracy and completeness of its prospectus, bearing legal responsibility for any false statements or omissions[141] Financial Management - The company has established a fundraising management system to ensure that raised funds are used specifically for designated projects[162] - The company will implement stock price stabilization measures if the average closing price over 20 consecutive trading days is below the latest audited net asset value per share[156] - The company will hold a board meeting within 5 trading days to discuss profit distribution or capital reserve conversion plans if stabilization measures are triggered[149]

Financial Performance - Net profit attributable to shareholders was ¥19,451,138.70, representing a significant increase of 451.46% year-on-year[6] - Operating revenue for the period was ¥50,843,046.14, marking a growth of 58.45% compared to the same period last year[6] - Basic earnings per share increased to ¥0.24, up 300% from ¥0.06 in the same period last year[6] - The weighted average return on equity rose to 1.42%, an increase of 0.48 percentage points compared to the previous year[6] - The company reported a net profit of ¥22,664,010.85 for Q1 2021, compared to a net profit of ¥7,796,297.11 in Q1 2020, marking a growth of 190.5%[34] - The total profit for Q1 2021 was ¥22,937,450.63, significantly higher than ¥3,943,656.35 in Q1 2020[36] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 196.98% to ¥19,344,242.74 from ¥6,513,612.94[20] Cash Flow - The net cash flow from operating activities was ¥6,453,318.56, a recovery from a negative cash flow of ¥10,916,233.02 in the previous year[6] - Net cash flow from operating activities improved by ¥17,369,551.58, resulting in a positive cash flow of ¥6,453,318.56 compared to a negative cash flow of -¥10,916,233.02 in the previous year[19] - The cash received from sales and services in Q1 2021 was ¥59,298,647.28, compared to ¥36,684,528.22 in Q1 2020, marking a 62% increase[40] - The company reported a net cash flow from operating activities of ¥6,475,152.93, compared to a negative cash flow of ¥10,917,731.64 in the same period last year[43] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,420,928,668.29, an increase of 1.39% compared to the end of the previous year[6] - Total liabilities stood at ¥94,285,057.85, showing a marginal increase from ¥94,243,107.00 at the end of 2020[30] - The company's equity attributable to shareholders reached ¥1,376,398,663.61, up from ¥1,356,672,782.50 at the end of 2020, representing a growth of 1.9%[31] - The total non-current liabilities amounted to ¥5,007,911.16, a significant increase from ¥1,569,678.66 at the end of 2020[30] - The company reported a total liability of CNY 45,312,936.30, with a total equity of CNY 1,356,152,023.97 as of the end of Q1 2021[47] Research and Development - R&D expenses grew by 38.71% to ¥4,124,300.79, attributed to higher personnel costs and product registration fees[17] - Research and development expenses for Q1 2021 were ¥4,124,300.79, an increase of 38.5% from ¥2,973,329.57 in Q1 2020[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,753[11] - The largest shareholder, Wu Shiming, holds 34.66% of the shares, totaling 28,298,431 shares[11] Financial Strategy and Accounting Changes - The company implemented revised accounting standards for leases, resulting in the recognition of right-of-use assets and lease liabilities[14] - The company has implemented new leasing standards starting from 2021, affecting the financial statements[44] - The company has opted for a simplified approach in implementing the new lease standards, without retrospective adjustments to prior periods[52]

Financial Performance - The proposed profit distribution plan for 2020 includes a cash dividend of RMB 4 per 10 shares, totaling RMB 32,659,200, which accounts for 47.20% of the net profit attributable to shareholders[6]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 15% year-over-year growth[16]. - In 2020, the company's operating revenue decreased by 3.12% year-on-year to CNY 222,398,393.41, primarily due to the impact of the COVID-19 pandemic on routine testing volumes in domestic medical institutions[26]. - The net profit attributable to shareholders decreased by 2.61% year-on-year to CNY 69,188,424.17, influenced by a donation of CNY 4,978,500 to support medical institutions during the pandemic[26]. - The company reported a total revenue of 82,811,600.00 RMB, with a net profit of 12,972,626.60 RMB, indicating a significant growth in financial performance compared to the previous year[70]. - The company achieved operating revenue of RMB 222.40 million, a year-on-year decrease of 3.12%, and a net profit attributable to shareholders of RMB 69.19 million, a decrease of 2.61%[84]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% year-over-year growth[155]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming for $1.875 billion[155]. Risk Management - The company has detailed various operational risks and corresponding countermeasures in the report, emphasizing the importance of risk management[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a substantive commitment to investors[7]. - The company faces risks related to potential technological changes in the thrombosis and hemostasis diagnostics market, which could impact existing products[89]. - The company may experience adverse effects on its operating performance if regional distributors fail to meet sales targets or if cooperation is disrupted[97]. - The company is exposed to foreign exchange risks due to sales and procurement in foreign currencies, which may impact operating performance[99]. - The company faces risks due to a single product structure and limited product registration certificates, which may not meet future market demands[96]. Governance and Compliance - The audit report issued by the accounting firm is a standard unqualified opinion, ensuring the accuracy of the financial statements[5]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The company has not faced any situations where more than half of the directors could not guarantee the authenticity of the annual report[11]. - The company has a comprehensive governance structure in place, ensuring accountability and transparency in its operations[9]. - The company is committed to maintaining the integrity and completeness of its financial reporting, as stated by the management team[6]. - The company has established a structured profit distribution system in place, including specific arrangements for cash dividends[145]. - The company will prioritize transparency and fairness in all related party transactions to safeguard shareholder interests[158]. Research and Development - The R&D expenditure accounted for 6.01% of operating revenue, slightly down from 6.04% in 2019[25]. - The company has established a core technology cluster in the field of thrombus and hemostasis in vitro diagnostics, covering five major technology categories[36]. - The company has developed 15 core technologies, including blood rheology measurement and coagulation diagnostic testing platforms, and holds 26 patents, of which 5 are invention patents[43]. - The company is focusing on the development of new technologies that improve the sensitivity and speed of plasma viscosity detection, which is crucial for clinical applications[48]. - The company is actively pursuing the commercialization of its D-dimer and FDP antibody products, which are expected to replace imported materials upon successful development[50]. - The company has a robust pipeline of research projects focused on thrombus and hemostasis diagnostics, leveraging its core technology platforms to expand its product line[76]. - The company plans to invest raised funds in production base construction and R&D center development to mitigate dilution of immediate returns[177]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[16]. - A strategic acquisition of a smaller biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional 150 million RMB in revenue by the end of 2021[16]. - The company is focusing on the development of high-performance fully automated coagulation testing instruments and specialized reagents to meet market trends[86]. - The company has established a nationwide marketing service network covering 29 provinces and key cities, excluding Tibet, Qinghai, and Hong Kong and Macau[79]. - The company has developed a competitive advantage in the domestic market by providing high-cost performance testing systems, successfully replacing imported products in secondary hospitals and below[78]. Shareholder Commitments - The controlling shareholder has committed to not transferring shares for 36 months post-IPO[148]. - The commitments outlined will remain effective throughout the company's listing period and until the controlling shareholder is no longer associated with the company[158]. - The controlling shareholder will notify the company of any competitive opportunities that may arise, ensuring they are offered to the company first[157]. - The company will adhere to all relevant regulations and internal rules regarding related party transactions to maintain compliance and protect shareholder rights[158]. - The company has a three-year shareholder dividend return plan post-IPO, which will be strictly followed[182]. Financial Position - The company's total assets at the end of 2020 reached CNY 1,401,464,960.27, an increase of 228.45% compared to the beginning of the year[26]. - The net assets attributable to shareholders increased by 261.94% year-on-year to CNY 1,356,152,023.97, bolstered by net proceeds of CNY 92,426,960 from the IPO[26]. - The company's total net profit attributable to shareholders for 2020 was RMB 69,188,424.17[146]. - The company’s cash dividend distribution plan is subject to approval at the annual general meeting[145]. Operational Efficiency - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[16]. - The company is investing 100 million RMB in new technology to improve production efficiency, aiming for a 30% reduction in operational costs[16]. - The company plans to implement cost-cutting measures aimed at reducing operational expenses by 5% over the next year[151]. - The company is focused on optimizing product structure and expanding overall scale to ensure sustainable development[178].

Financial Performance - Operating revenue for the year-to-date was ¥50,843,046.14, representing a 58.45% increase year-on-year[6]. - Net profit attributable to shareholders was ¥19,451,138.70, a significant increase of 451.46% compared to the same period last year[6]. - Basic and diluted earnings per share were both ¥0.24, reflecting a 300% increase year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥19,344,242.74, an increase of 196.98% year-on-year[6]. - The company reported a total comprehensive income of ¥19,451,138.70 for Q1 2021, compared to ¥3,527,198.52 in Q1 2020, highlighting strong financial performance[34]. - The net profit for Q1 2021 reached ¥19,725,881.11, a significant increase from ¥3,352,107.92 in Q1 2020, marking a growth of approximately 487%[35]. - The operating profit for Q1 2021 was ¥22,937,581.80, compared to ¥7,562,842.98 in Q1 2020, indicating a year-over-year increase of about 203%[35]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,420,928,668.29, an increase of 1.39% compared to the end of the previous year[6]. - The company’s total liabilities decreased by 58.74% in accounts receivable financing, down to ¥502,137.90, mainly due to the maturity of bank acceptance bills[14]. - Total liabilities were ¥45,325,505.62, showing a slight increase from ¥45,312,936.30 at the end of 2020[25]. - The total current assets decreased by 153,701.84 RMB, totaling 1,327,774,197.54 RMB[44]. - The company reported a total equity of 1,356,152,023.97 RMB, unchanged from the previous year[46]. - Total liabilities reached $94,243,107.00, reflecting a decrease of $6,085,906.30[50]. Cash Flow - Net cash flow from operating activities was ¥5,615,737.00, a recovery from a negative cash flow of ¥10,916,233.02 in the previous year[6]. - The company reported a net cash flow from operating activities of ¥5,615,737.00 in Q1 2021, a turnaround from a negative cash flow of ¥10,916,233.02 in Q1 2020[39]. - The cash inflow from operating activities totaled ¥63,950,201.16 in Q1 2021, compared to ¥39,378,594.13 in Q1 2020, showing improved operational efficiency[39]. - The net cash flow from financing activities was -424,528.30 RMB, indicating a cash outflow[43]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,753[11]. - The largest shareholder, Wu Shiming, holds 34.66% of the shares, totaling 28,298,431 shares[11]. Expenses - The cost of goods sold increased by 45.12%, amounting to ¥19,507,128.16, driven by the rise in operating revenue[15]. - Research and development expenses increased by 38.71% to ¥4,124,300.79, reflecting higher personnel costs and product registration fees[15]. - The company reported a 394.33% increase in income tax expenses, totaling ¥3,212,740.98, due to higher operating profits[16]. - The company’s management expenses rose by 35.10% to ¥3,019,415.55, driven by an increase in personnel and intermediary fees[16]. - The company incurred financial expenses of -¥7,344,804.98 in Q1 2021, compared to -¥2,321,449.34 in Q1 2020, indicating a change in financial strategy[35]. Government Subsidies - The company received government subsidies amounting to ¥125,909.09, which are closely related to its normal business operations[10]. Accounting Changes - The company adopted a new leasing standard starting January 1, 2021, resulting in an increase of right-of-use assets by 6,239,608.14 RMB and lease liabilities by 6,085,906.30 RMB[47]. - The company adopted the revised Accounting Standards for Leases starting January 1, 2021, resulting in an increase of $6,239,608.14 in right-of-use assets[51].

Financial Performance - Operating revenue for the first nine months decreased by 4.77% year-on-year, totaling CNY 151,135,602.87[7] - Net profit attributable to shareholders decreased by 16.05% year-on-year, amounting to CNY 40,158,932.04[7] - Basic earnings per share decreased by 29.63% to CNY 0.57[8] - The net profit attributable to shareholders decreased by 16.05%, primarily due to a reduction in routine testing volumes in domestic medical institutions caused by the COVID-19 pandemic, leading to a 4.77% decline in operating revenue[22] - The net profit for Q3 2020 was CNY 15,112,444.36, down from CNY 17,447,605.30 in Q3 2019, indicating a decrease of about 13.4%[42] - The total profit for Q3 2020 was CNY 17,823,480.99, slightly lower than CNY 20,028,438.23 in Q3 2019, showing a decline of about 10.9%[42] - The company's basic earnings per share for Q3 2020 were CNY 0.21, down from CNY 0.29 in Q3 2019, a decrease of approximately 27.6%[43] - The total comprehensive income for Q3 2020 was CNY 15,112,444.36, down from CNY 17,447,605.30 in Q3 2019, indicating a decline of approximately 13.4%[43] Assets and Liabilities - Total assets increased by 219.98% year-on-year, reaching CNY 1,365,319,400.68 at the end of the reporting period[7] - Total liabilities reached CNY 38,196,868.84, down from CNY 51,997,723.42 year-over-year[38] - Total equity attributable to shareholders increased to CNY 1,327,122,531.84 from CNY 374,693,962.58, reflecting strong growth in retained earnings[34] - The company's total liabilities decreased by approximately 26.5% year-over-year, indicating improved financial health[38] - The company’s total liabilities were reported at ¥51,997,723.42, remaining consistent with the previous year, which reflects effective liability management[52] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 29,456,685.13, a decrease of 1.96% year-on-year[7] - The net cash flow from operating activities decreased primarily due to the reduction in operating revenue[21] - The net cash flow from investing activities showed a significant decline of 581.72%, from -CNY 4,556,016.32 in 2019 to -CNY 31,059,154.12 in 2020[23] - The net cash flow from financing activities increased by 748.95%, rising from CNY 107,500,363.98 in 2019 to CNY 912,623,588.23 in 2020[23] - Cash flow from operating activities for the first nine months of 2020 was CNY 191,503,072.86, up from CNY 181,312,285.32 in the first nine months of 2019, reflecting a growth of approximately 5.67%[46] - The net cash flow from financing activities in Q3 2020 was CNY 912,623,588.23, significantly higher than CNY 107,500,363.98 in Q3 2019, showing an increase of about 748.57%[47] Shareholder Information - The company had a total of 10,752 shareholders at the end of the reporting period[12] - The largest shareholder, Wu Shiming, holds 34.66% of the shares, totaling 28,298,431 shares[12] Research and Development - Research and development expenses accounted for 6.75% of operating revenue, an increase of 0.50 percentage points compared to the previous year[8] - Research and development expenses increased by 2.81% to approximately ¥10.20 million, reflecting ongoing investment in new technologies[18] - Research and development expenses for Q3 2020 were CNY 3,403,955.33, compared to CNY 3,238,793.55 in Q3 2019, reflecting an increase of approximately 5.1%[44] Government Subsidies and Other Income - The company reported a government subsidy of CNY 1,336,817.32 related to its normal business operations[9] - Other income increased by 100.62%, primarily due to an increase in government subsidies related to income[24] Market Outlook - The company anticipates a gradual recovery in testing volumes as the domestic COVID-19 situation stabilizes, although year-to-date testing volumes remain lower than the previous year[14] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[39] Equity and Capital - The company completed a public offering of 20.41 million shares in July 2020, raising a net amount of approximately ¥924.27 million, significantly increasing its cash reserves by 281.94%[15][16] - The company issued 20,412,000 shares on August 6, 2020, raising a net amount of CNY 92,426.96 million, which increased the total share capital to CNY 8164.8 million[26] Intangible Assets - The company reported a significant increase in intangible assets by 3,821.20%, primarily due to the acquisition of land use rights by its subsidiary[19] Financial Ratios - The weighted average return on equity decreased by 17.44 percentage points, primarily due to the issuance of new shares and the decline in net profit attributable to shareholders[28]

Financial Performance - The company reported a significant increase in revenue for the first half of 2020, with a total revenue of RMB 500 million, representing a 25% year-over-year growth[1]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2020, representing a 25% year-over-year growth[14]. - Operating revenue for the first half of the year was CNY 99,194,115.13, a decrease of 9.13% year-on-year[21]. - Net profit attributable to shareholders decreased by 17.59% to CNY 25,046,487.68 compared to the same period last year[21]. - Basic earnings per share decreased by 22.64% to CNY 0.41 compared to the same period last year[20]. - The company reported a total revenue of 46,030,000.00 RMB for the first half of 2020, with a net profit of 40,608,892.43 RMB, indicating a significant performance in the market[51]. - The company’s comprehensive income for the current period was CNY 25,046,487.68, reflecting a significant increase compared to the previous year's comprehensive income of CNY 71,040,074.50[129]. User Growth and Market Expansion - User data showed an increase in active users, reaching 1.2 million, which is a 30% increase compared to the previous year[1]. - User data indicates that the number of active users has reached 500,000, marking a 30% increase compared to the previous year[14]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market penetration by the end of 2021[1]. - Market expansion efforts include entering three new provinces, which are anticipated to increase market share by 15%[14]. Product Development and Innovation - New product development includes the launch of a next-generation diagnostic device, expected to increase market share by 15%[1]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of the year[14]. - The company is investing RMB 50 million in R&D for innovative technologies in the IVD sector[1]. - The company is investing heavily in R&D, with an allocation of 150 million RMB for the development of new technologies and products[14]. - The company is focusing on expanding its product line in the thrombosis and hemostasis in vitro diagnostic field, with a rich reserve of ongoing research projects[56]. Financial Health and Management - The gross margin improved to 60%, up from 55% in the previous year, indicating better cost management[1]. - The company's R&D expenditure as a percentage of operating revenue increased by 0.73 percentage points to 6.85%[20]. - The net assets attributable to shareholders increased by 3.48% to CNY 387,740,450.26 compared to the end of the previous year[21]. - Total assets increased by 1.60% to CNY 433,522,949.52 compared to the end of the previous year[21]. - The company has maintained its business model of "independent R&D and production, sales-driven production, and distribution-focused sales" throughout the reporting period[26]. Strategic Initiatives - A strategic acquisition of a local competitor was announced, which is expected to enhance the company's product offerings and increase revenue by an estimated RMB 100 million annually[1]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of 300 million RMB allocated for this purpose[14]. - A new strategic partnership has been established with a leading healthcare provider, expected to drive additional revenue of 100 million RMB annually[14]. Operational Efficiency - The company has implemented new strategies to enhance operational efficiency, aiming for a 15% reduction in operational costs by the end of 2020[1]. - Operating costs decreased by 6.04% compared to the same period last year, primarily due to a reduction in operating income[70]. - Sales expenses decreased by 10.98%, mainly due to reduced spending on meetings and travel as a result of the COVID-19 pandemic[70]. Research and Development - The company has established a core technology cluster in the field of thrombus and hemostasis in vitro diagnostics, encompassing 15 proprietary technologies[39]. - The company has developed 15 core technologies, including blood rheology measurement and coagulation diagnosis testing technology, which have received multiple national and local awards[55]. - The company has a total of 43 R&D personnel, accounting for 15.30% of the total workforce, with a total R&D compensation of 4,129,200.04 RMB and an average salary of 96,027.91 RMB[53]. Environmental and Compliance - The company reported no significant environmental penalties during the reporting period, adhering to environmental regulations and ensuring compliance in production management[84]. - The company’s solid waste management includes recycling of general industrial solid waste and proper disposal of hazardous waste, with contracts in place for waste treatment[85]. - The company’s wastewater treatment processes involve integrated facilities that ensure compliance with municipal standards, with no major environmental violations reported[86]. Challenges and Risks - The COVID-19 pandemic has increased demand for diagnostic products, although it has also led to a decline in routine medical product demand due to reduced patient visits[38]. - The company faced risks related to limited market space for blood flow detection products and reliance on a single foreign supplier for key raw materials[64][65]. - The company anticipates potential risks of declining performance in 2020 compared to 2019 if the COVID-19 pandemic continues[65]. Shareholder Information - The company issued 20.41 million A-shares on August 6, 2020, raising a net amount of approximately 924.27 million yuan, increasing total shares to 81.648 million[92]. - The total owner's equity at the end of the reporting period was CNY 387,740,450.26, up from CNY 195,653,524.10 in the previous year, indicating a growth of about 97.9%[127].